retatrutide nonalcoholic steatohepatitis nash trial fatty liver disease Retatrutide, the triple G, Glucagon-GIP-GLP-1 based triagonist produces substantial resolution of liver fat #NAFLD in PPL with #obesity #ADA2023 @ADA_DiabetesPro @AmDiabetesAssn #NASH trial coming retatrutide nonalcoholic fatty liver disease

Sitagliptin (Aschner et al., 2009), and vildagliptin (Keating, 2010) all improve glucose metabolism in diabetic patients

Image credit: Tetiana_Kryvous/Shutterstock.com A new study in the Medical Journal of Australia examines the use of glucagon-like peptide 1 (GLP-1) receptor agonists (RAs) in reproductive-age women in Australia to effectively manage type 2 diabetes mellitus, along with contraception overlap and pregnancy incidence in this population

You can also typically use them twice daily without an adjustment period, unlike many other active ingredients

Clinical data support the radioprotective function of honey

The rise of GLP-1 weight loss medications, such as Wegovy and Ozempic are revolutionizing weight management

Targeted skin care can make a difference in some areas